Antibodies
31 August 2011
Richter and STADA cooperate for development of two biosimilar products, two monoclonal antibodies: Rituximab and Trastuzumab29 August 2011
Zymeworks Inc. Announces Collaboration with Merck to Develop Bi-specific Antibody Therapeutics25 August 2011
Peregrine Reports Promising 20.7 Month Median Overall Survival From Phase II Advanced Breast Cancer Trial23 August 2011
Seattle Genetics Announces Initiation of a Phase II Clinical Trial of ADCETRIS in CD30-Positive Non-Hodgkin Lymphoma22 August 2011
Oncobiologics, Inc. and Fox Chase Cancer Center Announce Co-Development of a Novel Cancer Therapy Platform19 August 2011
Seattle Genetics Announces FDA Accelerated Approval of ADCETRIS (Brentuximab Vedotin) for Two Indications17 August 2011
Regeneron Announces Review of Biologics License Application for EYLEA (aflibercept injection) Extended by Three Months by FDA5 August 2011
Roche’s RoACTEMRA approved in Europe for children living with a rare and severe form of arthritis5 August 2011
Roche’s investigational treatment for asthma met its primary endpoint in a phase II study1 August 2011
Humabs discovers the first antibody to neutralize both group 1 and group 2 influenza A virusesNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports